3D in vitro model for atopic dermatitis

Commonly used acronym: RHE-AD

Scope of the method

The Method relates to
  • Human health
The Method is situated in
  • Basic Research
Type of method
  • In vitro - Ex vivo
This method makes use of
  • Human derived cells / tissues / organs
Specify the type of cells/tissues/organs
Reconstructed human Epidermis


Method keywords
  • LXR
  • preclinical
  • skin model
  • therapeutic
  • in vitro
Scientific area keywords
  • dermatitis
  • Skin equivalents
  • drug screening
  • Atopic dermatitis
  • Skin barrier
  • cytokines
Method description

Recent advances in the development of human-based in vitro models offer new tools for drug screening and mechanistic investigations of new therapeutic agents. However, there is a lack of evidence that disease models respond favourably to potential drug candidates. Atopic dermatitis (AD) is a very common disease associated with an altered skin barrier and chronic inflammation. Here, we demonstrate that the AD-like features of a reconstructed human epidermis (RHE) model treated with Th2 cytokines are reversed in the presence of molecules known to have a beneficial effect on damaged skin as a result of modulating various signalling cascades including the Liver X Receptors and JAK/STAT pathways. This work shows that standardized and reproducible RHE are relevant models for therapeutic research assessing new drug candidates aiming to restore epidermal integrity in an inflammatory environment.

Method status
  • Internally validated
  • Published in peer reviewed journal

References, associated documents and other information


DOI: 10.1111/exd.13810

Associated documents
Hubaux et al. 2018_Exp Derma.pdf
company website
company linkedin

Contact person

Christel Boudry